U.S. flag

An official website of the United States government

NM_007194.4(CHEK2):c.1427C>T (p.Thr476Met) AND Hereditary cancer-predisposing syndrome

Germline classification:
Conflicting interpretations of pathogenicity (7 submissions)
Last evaluated:
Jan 17, 2024
Review status:
criteria provided, conflicting classifications
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000116001.34

Allele description [Variation Report for NM_007194.4(CHEK2):c.1427C>T (p.Thr476Met)]

NM_007194.4(CHEK2):c.1427C>T (p.Thr476Met)

Gene:
CHEK2:checkpoint kinase 2 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
22q12.1
Genomic location:
Preferred name:
NM_007194.4(CHEK2):c.1427C>T (p.Thr476Met)
Other names:
p.T476M:ACG>ATG
HGVS:
  • NC_000022.11:g.28694066G>A
  • NG_008150.2:g.52801C>T
  • NM_001005735.2:c.1556C>T
  • NM_001257387.2:c.764C>T
  • NM_001349956.2:c.1226C>T
  • NM_007194.4:c.1427C>TMANE SELECT
  • NM_145862.2:c.1340C>T
  • NP_001005735.1:p.Thr519Met
  • NP_001244316.1:p.Thr255Met
  • NP_001336885.1:p.Thr409Met
  • NP_009125.1:p.Thr476Met
  • NP_665861.1:p.Thr447Met
  • LRG_302t1:c.1427C>T
  • LRG_302:g.52801C>T
  • LRG_302p1:p.Thr476Met
  • NC_000022.10:g.29090054G>A
  • NG_008150.1:g.52769C>T
  • NM_001005735.1:c.1556C>T
  • NM_007194.3:c.1427C>T
  • p.T476M
Protein change:
T255M
Links:
dbSNP: rs142763740
NCBI 1000 Genomes Browser:
rs142763740
Molecular consequence:
  • NM_001005735.2:c.1556C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001257387.2:c.764C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001349956.2:c.1226C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_007194.4:c.1427C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_145862.2:c.1340C>T - missense variant - [Sequence Ontology: SO:0001583]
Observations:
2

Condition(s)

Name:
Hereditary cancer-predisposing syndrome
Synonyms:
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000186804Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Established risk allele
(Nov 4, 2022)
germlineclinical testing

PubMed (9)
[See all records that cite these PMIDs]

Citation Link,

SCV000576430Institute for Biomarker Research, Medical Diagnostic Laboratories, L.L.C.
criteria provided, single submitter

(ACMG Guidelines, 2015)
Likely pathogenic
(Feb 14, 2017)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV000680448GeneID Lab - Advanced Molecular Diagnostics
criteria provided, single submitter

(ACMG Guidelines, 2015)
Likely pathogenic
(Sep 7, 2017)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV000689655Color Diagnostics, LLC DBA Color Health
criteria provided, single submitter

(ACMG Guidelines, 2015)
Uncertain significance
(Jan 17, 2024)
germlineclinical testing

PubMed (30)
[See all records that cite these PMIDs]

SCV000821724GeneKor MSA
criteria provided, single submitter

(ACMG Guidelines, 2015)
Likely pathogenic
(Jan 9, 2021)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV001448806Knight Diagnostic Laboratories, Oregon Health and Sciences University
criteria provided, single submitter

(ACMG Guidelines, 2015)
Likely pathogenic
(Mar 12, 2019)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV002537374Sema4, Sema4
criteria provided, single submitter

(Sema4 Curation Guidelines)
Uncertain significance
(Feb 5, 2022)
germlinecuration

PubMed (15)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyesnot providednot providednot providednot providednot providedclinical testing
not providedgermlineunknown1not providednot providednot providednot providedclinical testing, curation
Caucasiangermlineunknown1not providednot providednot providednot providedclinical testing

Citations

PubMed

Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing.

BalmaƱa J, Digiovanni L, Gaddam P, Walsh MF, Joseph V, Stadler ZK, Nathanson KL, Garber JE, Couch FJ, Offit K, Robson ME, Domchek SM.

J Clin Oncol. 2016 Dec;34(34):4071-4078. Epub 2016 Sep 30.

PubMed [citation]
PMID:
27621404
PMCID:
PMC5562435

Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care-Checking CHEK2.

Bychkovsky BL, Agaoglu NB, Horton C, Zhou J, Yussuf A, Hemyari P, Richardson ME, Young C, LaDuca H, McGuinness DL, Scheib R, Garber JE, Rana HQ.

JAMA Oncol. 2022 Nov 1;8(11):1598-1606. doi: 10.1001/jamaoncol.2022.4071.

PubMed [citation]
PMID:
36136322
PMCID:
PMC9501803
See all PubMed Citations (36)

Details of each submission

From Ambry Genetics, SCV000186804.10

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (9)

Description

The p.T476M variant (also known as c.1427C>T), located in coding exon 12 of the CHEK2 gene, results from a C to T substitution at nucleotide position 1427. The threonine at codon 476 is replaced by methionine, an amino acid with similar properties. Recent case-control studies have reported association with breast cancer risk with odds ratios ranging from 1.35 to 1.63 (Dorling et al. N Engl J Med. 2021 02;384:428-439; Bychkovsky BL et al. JAMA Oncol. 2022 Sep). Functional studies of this alteration have reported conflicting findings. In one in vivo, yeast-based growth rate assay, this variant was indicated to be semi-functional (Delimitsou A. Hum Mutat. 2019 05;40(5):631-648). However, several other studies have reported the variant as deleterious based on kinase and DNA damage response activity (Desrichard A et al. Breast Cancer Res. 2011 Nov;13:R119; Roeb W et al. Hum. Mol. Genet. 2012 Jun;21:2738-44). Another study reported this alteration as deleterious in an in vitro assay of kinase activity using bacterially expressed CHEK2, but neutral in an assay conducted in a human cell line (Kleiblova P et al Int J Cancer. 2019 10;145(7):1782-1797). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the majority of available evidence to date, this variant is interpreted as a moderate risk mutation, also referred to as an established risk allele.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Institute for Biomarker Research, Medical Diagnostic Laboratories, L.L.C., SCV000576430.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From GeneID Lab - Advanced Molecular Diagnostics, SCV000680448.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1Caucasian1not providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot provided1not providednot providednot provided

From Color Diagnostics, LLC DBA Color Health, SCV000689655.6

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (30)

Description

This missense variant replaces threonine with methionine at codon 476 of the CHEK2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). Functional studies have demonstrated inconsistent results. The mutant protein has shown significantly reduced kinase activity in vitro using bacteria produced protein (PMID: 22114986, 31050813), but displayed normal kinase activity in a human cell assay (PMID: 31050813, 37449874). DNA damage repair assays in yeast have shown the mutant protein to exhibit partial to complete loss of function (PMID: 22419737, 30851065). This variant has been reported in individuals affected with breast cancer (PMID: 15095295, 21244692, 22114986, 22862163, 24595525, 25186627, 26681312, 28008555, 28495237 30426508, 32658311, 32805687, 32906215, 33030641, 36315097, 37628581), prostate cancer (PMID: 29368341, 29520813), colorectal cancer (PMID: 28008555, 28135145, 28944238, 32658311), pancreatic cancer (PMID: 26483394, 26845104 29945567), and endometrial cancer (PMID: 27443514), as well as in individuals unaffected with cancer (PMID: 32658311). A history weighting algorithm score was inconsistent with that expected for CHEK2 pathogenic mutations (Mundt, et al. poster #154, ACMG 2017). This variant has been identified in 83/265178 chromosomes in the general population by the Genome Aggregation Database (gnomAD). This variant has been reported in two large case-control meta analyses; this variant has been identified in 83/60383 cases and 45/53416 controls (OR=1.632, 95%CI [1.135 to 2.346]) (PMID: 33471991) and 101/73048 BC cases and 60/88658 controls (OR=2.043, 95%Ci [1.4841 to 2.8125]) (PMID: 37449874). In summary, functional studies have been inconclusive regarding the impact of this variant on protein function, and this variant has been observed in individuals affected with breast cancer as well as in the general population. The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From GeneKor MSA, SCV000821724.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

This variation detected results in the substitution of the amino acid Threonine with Methionine at codon 476 of the CHEK2 protein. The threonine residue is highly conserved among species in the Protein kinase domain of the protein and there is physiochemical difference between threonine and methionine (Grantham Score 81). This variant has been described in the international literature in individuals affected with breast and endometrial cancers (PMID: 21244692, PMID: 27443514).This variant is present in mutation databases at a low frequency (rs142763740, ExAC 0.07%). The mutation database ClinVar contains entries for this variant (Variation ID: 128060). Algorithms developed to predict the effect of missense changes on protein structure and function suggest that this variant is likely to be damaging to the protein, a prediction supported also by experimental studies. (PMID: 22114986, PMID: 22419737).

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot providednot providednot providednot providednot provided

From Knight Diagnostic Laboratories, Oregon Health and Sciences University, SCV001448806.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided1not providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot provided1not providednot providednot provided

From Sema4, Sema4, SCV002537374.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedcuration PubMed (15)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 8, 2024